Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft ver...

Incyte Genomics Inc (INCY) has a valuation score of 67/100 (moderate), profitability score of 95/100 (strong), financial health score of 100/100 (strong), Piotroski F-Score of 8/9, Altman Z-Score of 10.05 (safe zone), revenue growth of +14.8% YoY.

Neutral

Analyst Consensus

Buy

Wall Street consensus estimates — not a PMP forecast · Updated Sep 2, 2026

Analyst Recommendations35 analysts · 2026-09-01
8
10
17
Strong Buy 8Buy 10Hold 17Sell 0Strong Sell 0
Incyte Genomics Inc (INCY) Valuation & P/E History →Incyte Genomics Inc (INCY) Financial Statements →
Share:

Explore More Stocks

AAPLMSFTNVDAGOOGLAMZNMETATSLAJPMWMTVView all stocks →